KEYTRUDA subkutan 395 mg/2.4 ml sol inj 395 mg 1 p

7680702530017 CH-70253 L01FF02 07.16.1.

Active substances:

Pembrolizumabum

No images available

Details

Product number
7025301
CPT
-
Packaging group
1
Unit
Durchstechflasche(n)
Composition
pembrolizumabum 395 mg, berahyaluronidasum alfa, natrii chloridum corresp. natrium 23 µg, histidinum, histidini hydrochloridum monohydricum, methioninum, saccharum, polysorbatum 80, aqua ad iniectabile q.s. ad suspensionem pro 2.4 ml.

Articles (1)

Keytruda subkutan 395 mg/2.4 ml, Injektionslösung
Injektionslösung
1
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Professional SmPC
Allemand
04/06/2026
Professional SmPC
Français
04/06/2026
Professional SmPC
Italien
04/06/2026

Detailed composition

Substance Quantity Type Category
pembrolizumabum
395.0 MG Substance Wirkstoff (Principe actif)
berahyaluronidasum alfa
- Substance HNIDK
natrii chloridum
- Substance HNIDK
natrium
23.0 UG Substance HBESI
histidinum
- Substance HNIDK
histidini hydrochloridum monohydricum
- Substance HNIDK
methioninum
- Substance HIMDK
saccharum
- Substance HNIDK
polysorbatum 80
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK

Reimbursement information

Public price
CHF 4294.10
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/08/2026

Authorization holder

MSD Merck Sharp & Dohme AG

6005 Luzern

Authorization information

Swissmedic authorization number
70253
Drug name
Keytruda subkutan, Injektionslösung
Galenic form
LSINJ
ATC Code
L01FF02
Authorization status
Z
Dispensation category
A
First authorization
01/06/2026
Authorization expiration date
31/05/2031
IT number
07.16.1.
Domain
Human medicine
Field of application
Melanom, Nicht-kleinzelliges Lungenkarzinom, Malignes Pleuramesotheliom, Kopf- und Halskarzinom, Klassisches Hodgkin Lymphom, B-Zell-Lymphom, Magenkarzinom, Urothelkarzinom, Tumore mit hoher Mikrosatelliteninstabilität, Kolorektales Karzinom, Biliäres Karzinom, Nierenzellkarzinom, Triple-negatives Mammakarzinom, Endometriumkarzinom, Zervixkarzinom

Packaging details

Description (FR)
KEYTRUDA subkutan 395 mg/2.4 ml sol inj 395 mg 1 p
Description (DE)
KEYTRUDA subkutan 395 mg/2.4 ml Inj Lös 395 mg 1 S
Market launch
01/08/2026
Narcotic (BTM)
No

Other packaging sizes

KEYTRUDA subkutan 790 mg/4.8 ml sol inj 790 mg 1 p
1 DUR
GTIN: 7680702530024
View
Buy us a coffee Explore the data